GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turning Point Therapeutics Inc (NAS:TPTX) » Definitions » Cash Flow from Investing

Turning Point Therapeutics (Turning Point Therapeutics) Cash Flow from Investing : $109.19 Mil (TTM As of Jun. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Turning Point Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2022, Turning Point Therapeutics spent $1.53 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $29.75 Mil on purchasing investments. It gained $108.22 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Turning Point Therapeutics gained $76.94 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2022.


Turning Point Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Turning Point Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Cash Flow from Investing Chart

Turning Point Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Investing
-0.09 -0.30 -361.08 -210.03 5.46

Turning Point Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.27 17.44 75.22 -60.41 76.94

Turning Point Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Turning Point Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2021 is calculated as:

Turning Point Therapeutics's Cash Flow from Investing for the quarter that ended in Jun. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $109.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turning Point Therapeutics  (NAS:TPTX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Turning Point Therapeutics's purchase of property, plant, equipment for the three months ended in Jun. 2022 was $-1.53 Mil. It means Turning Point Therapeutics spent $1.53 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Turning Point Therapeutics's sale of property, plant, equipment for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Turning Point Therapeutics's purchase of business for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Turning Point Therapeutics's sale of business for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Turning Point Therapeutics's purchase of investment for the three months ended in Jun. 2022 was $-29.75 Mil. It means Turning Point Therapeutics spent {stock_data.stock.currency_symbol}}29.75 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Turning Point Therapeutics's sale of investment for the three months ended in Jun. 2022 was $108.22 Mil. It means Turning Point Therapeutics gained $108.22 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Turning Point Therapeutics's net Intangibles purchase and sale for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Turning Point Therapeutics's cash from discontinued investing activities for the three months ended in Jun. 2022 was 0.00 Mil. It means Turning Point Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Turning Point Therapeutics's cash from other investing activities for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics paid $0.00 Mil for other investing activities.


Turning Point Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Turning Point Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Turning Point Therapeutics (Turning Point Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Executives
Paolo Tombesi officer: EVP & Chief Financial Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Steve M Sabus officer: SVP & Chief Commercial Officer 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Brian Sun officer: SVP & General Counsel C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Mohammad Hirmand officer: EVP and Chief Medical Officer C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Athena Countouriotis director, officer: President & CEO C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Siegfried Reich officer: EVP & Chief Scientific Officer 10505 ROSELLE STREET SAN DIEGO CA 92121
Andrew John Partridge officer: EVP & Chief Commercial Officer C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109
Annette North officer: EVP, General Counsel & Secty. C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Van Hoose Kyri K. officer: Principal Accounting Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Brian Lee Baker officer: VP of Finance and Admin. C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Yi Larson officer: EVP & Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Jingrong Jean Cui director, 10 percent owner, officer: Chief Scientific Officer C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428

Turning Point Therapeutics (Turning Point Therapeutics) Headlines